Evaluating a new chemotherapy regimen for relapsed or refractory AML

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the safety and efficacy of a novel chemotherapy regimen called DCMG, which includes decitabine, azacitidine, mitoxantrone liposome, cytarabine, and G-CSF, for patients with relapsed or refractory acute myeloid leukemia (AML). The study aims to assess how well this combination therapy works in treating AML that has not responded to previous treatments. Participants will be closely monitored for both the effectiveness of the treatment and any potential side effects. The trial is designed to provide insights into a new approach for managing this challenging condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The patient has fully understood the study, voluntarily agrees to participate, and has signed the Informed Consent Form (ICF);
* Age between 18 and 75 years, with no gender restrictions;
* Confirmed diagnosis of relapsed/refractory AML (Acute Myeloid Leukemia) by pathology (meeting any one of the following criteria):

  1. Patients who meet the diagnostic criteria for acute myeloid leukemia (AML) with minimal residual disease (MRD) positivity;
  2. Or patients who meet the diagnostic criteria for recurrent AML, or refractory AML;
* Serum total bilirubin ≤ 1.5 times the upper limit of normal, serum ALT and AST both ≤ 2.5 times the upper limit of the normal range, serum creatinine ≤ 1.5 times the upper limit of normal;
* Echocardiogram showing left ventricular ejection fraction (LVEF) ≥ 50%;
* Estimated survival time ≥ 3 months;
* ECOG performance status score of 0-2.

Exclusion Criteria:

* The subject's prior anti-tumor treatment history meets one of the following conditions:

  1. Previously received mitoxantrone or mitoxantrone hydrochloride liposome injection;
  2. Previously received doxorubicin or other anthracyclines, with a total cumulative dose of doxorubicin \> 360 mg/m² (other anthracycline drugs are converted at a ratio of 1 mg doxorubicin equivalent to 2 mg daunorubicin or 0.5 mg idarubicin);
* Cardiac function and disease meet any of the following conditions:

  1. Long QTc syndrome or QTc interval \> 480 ms;
  2. Complete left bundle branch block, second-degree or third-degree atrioventricular block;
  3. Severe, uncontrolled arrhythmia requiring medication;
  4. New York Heart Association (NYHA) classification ≥ Class II;
  5. Ejection fraction (EF) \< 50% or below the lower limit of normal for the study center's laboratory;
  6. History of myocardial infarction, unstable angina, severe unstable ventricular arrhythmias, or any other arrhythmia requiring treatment, clinically significant pericardial disease, or evidence on electrocardiogram of acute ischemia or active conduction system abnormalities within 6 months prior to enrollment.
* Underwent any major surgery, radiotherapy, chemotherapy, biological therapy, immunotherapy, or experimental treatment within 2 weeks before the first administration of the study drug;
* Uncontrolled systemic diseases (such as progressive infections, uncontrolled hypertension, diabetes, etc.);
* Previous or current diagnosis of other malignancies (excluding adequately controlled basal cell carcinoma of the skin that is non-melanoma, breast/cervical carcinoma in situ, or other malignancies that have been adequately controlled without treatment in the past five years);
* Active hepatitis B or C infection during the viremic phase (Hepatitis B testing: if either HBsAg or core antibody is positive, add HBV-DNA testing; viral DNA levels exceeding 1x10\^3 copies/mL; Hepatitis C testing: if HCV antibody is positive, add HCV-RNA testing; viral RNA levels exceeding 1x10\^3 copies/mL);
* Human Immunodeficiency Virus (HIV) infection (HIV antibody positive);
* Pregnant women, breastfeeding women, patients who refuse to use effective contraception during the study period;
* Significant neurological or psychiatric history;
* Patients deemed unsuitable for participation in this study by the investigator.

Where it's running

• Chinese PLA General Hospital
  Beijing, China Recruiting

Study contacts

• Study coordinator: Dr. Gao Xiaoning, Chief Physician, Professor
• Email: gaoxn@263.net
• Phone: 86+01066947169

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CRD3874-SI in People with Leukemia

  A small early-stage study tests CRD3874-SI to see if it is safe for adults with relapsed or refractory acute myeloid leukemia.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07661095

• New treatment for patients with relapsed acute myeloid leukemia

  This study is testing a new treatment called CER-1236 to see if it can help people with relapsed acute myeloid leukemia feel better and improve their chances of recovery.

  Recruiting at 5 sites Phase 1 CERo Therapeutics Holdings, Inc. · Sacramento, California and 4 other locations · NCT06834282

• Combining tagraxofusp with low-intensity chemotherapy for treating specific types of leukemia

  This study is testing a new treatment combining tagraxofusp with low-intensity chemotherapy to see if it helps people with certain types of leukemia that haven't responded to previous treatments.

  Recruiting Phase 1/2 Stanford University · Palo Alto, California · NCT06561152

• Combining PD-1 inhibitor with venetoclax for treating tough cases of leukemia and myelodysplastic syndromes

  This study is testing a new treatment that combines three drugs to see if it can help people with tough cases of leukemia and myelodysplastic syndromes who haven't responded to other treatments.

  Recruiting Phase 2 Beijing 302 Hospital · Beijing, Beijing Municipality · NCT06536959

• Combining revumenib, azacitidine, and venetoclax for treating pediatric and young adult patients with tough cases of acute myeloid leukemia

  This study is testing a new combination of drugs to see if it can help young patients with tough cases of acute myeloid leukemia feel better and achieve remission.

  Recruiting at 10 sites Phase 1 St. Jude Children's Research Hospital · San Diego, California and 9 other locations · NCT06177067

• Using CAR T cells to treat acute myeloid leukemia

  This study is testing a new treatment using specially modified CAR T cells to see if it can safely help adults and kids with tough cases of acute myeloid leukemia.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06017258

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.